- 10x Genomics Inc TXG reported Q3 sales of $125.3 million, beating the consensus of $122.62 million.
- Sales increased 74% Y/Y, primarily due to increased consumables revenue driven by growth in the instrument installed base.
- The gross margin remained flat at 80% as the impact in shifting product mix offset lower accrued royalties related to the Bio-Rad litigation.
- The company's net loss for the quarter narrowed to $(17.2) million, or $(0.15) per share, compared to a net loss of $(65.8) million, beating the consensus Wall Street analyst estimate of $(0.20).
- 10x Genomics had $600.4 million in cash and cash equivalents at the end of Q3.
- Guidance: The Company revised its FY21 revenue guidance to $490 million and $500 million, higher than the prior guidance of $480 million - $500 million.
- Price Action: TXG shares closed at $164.16 on Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in